Show simple item record

dc.contributor.authorOwen, Len
dc.contributor.authorMonaghan, Phillip Jen
dc.contributor.authorArmstrong, Anne Cen
dc.contributor.authorKeevil, Ben
dc.contributor.authorHigham, Claire Een
dc.contributor.authorSalih, Zenaen
dc.contributor.authorHowell, Sacha Jen
dc.date.accessioned2019-03-04T12:32:43Z
dc.date.available2019-03-04T12:32:43Z
dc.date.issued2019en
dc.identifier.citationOwen LJ, Monaghan PJ, Armstrong A, Keevil BG, Higham C, Salih Z, et al. Oestradiol measurement during fulvestrant treatment for breast cancer. Br J Cancer. 2019 Jan 25.en
dc.identifier.pmid30679781en
dc.identifier.doi10.1038/s41416-019-0378-9en
dc.identifier.urihttp://hdl.handle.net/10541/621563
dc.description.abstractBiochemical evaluation of menopausal status is used to inform treatment decisions, including clinical trial eligibility in women with oestrogen receptor positive breast cancer. However, fulvestrant may interfere with oestradiol immunoassays and confound accurate assessment in this context. We conducted a service evaluation of two immunoassays and an LC-MS/MS assay to determine the extent of the interference. Serum oestradiol levels were analysed by two immunoassays (Siemens Centaur XP and Abbott Architect) and liquid chromatography-tandem mass spectrometry (LC/MS/MS). Immunoassay gave higher serum oestradiol results than LC-MS/MS at low concentrations, with improved analytical sensitivity demonstrated by LC-MS/MS. Cross-reactivity of fulvestrant was observed for each immunoassay. We have shown that two commonly used immunoassays do not demonstrate the required sensitivity or specificity for the measurement of oestradiol in a breast cancer population. For patients receiving fulvestrant, spurious results may be generated that could impact treatment decisions. LC-MS/MS is recommended in this setting.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41416-019-0378-9en
dc.titleOestradiol measurement during fulvestrant treatment for breast cancer.en
dc.typeArticleen
dc.contributor.departmentBiochemistry Department, Wythenshawe Hospital, Wythenshawe, M23 9LT, UKen
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record